Quoin Pharmaceuticals (QNRX) Accumulated Expenses (2020 - 2026)

Quoin Pharmaceuticals has reported Accumulated Expenses for 7 years, with the latest figure at $1.8 million in Q1 2026.

• Quarterly Accumulated Expenses fell 26.03% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 26.03% YoY) and the FY2025 annual result came in at $2.5 million, up 66.02% from the prior year.
• Accumulated Expenses fell to $1.8 million in Q1 2026 per QNRX's latest filing, from $2.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.6 million in Q3 2023 and troughed at $1.2 million in Q4 2022.
• A 5-year average of $1.9 million and a median of $1.8 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 101.32% in 2022, then sank 41.99% in 2024.
• Over 5 years, Accumulated Expenses stood at $1.2 million in 2022, then advanced by 11.31% to $1.3 million in 2023, then climbed by 16.83% to $1.5 million in 2024, then surged by 66.02% to $2.5 million in 2025, then slipped by 28.16% to $1.8 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.8 million, $2.5 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.